Certara ups drug evidence and access offering
Certara adds Compass Strategic Consulting’s team to its evidence and access group, which helps customers build product value propositions.
Archives for July 22, 2019
Astellas licenses Frequency’s lead drug for $625m
Astellas agrees a deal for the ex-US rights of Frequency’s lead drug candidate, FX-322, after the latter company posted positive results in a Phase I/II trial.
Novartis sells treatment rights to Recordati for $390m
Recordati acquires Novartis’ Signifor, a treatment for Cushing’s syndrome, along with rights for an investigational drug, in a $390m deal.
Biohaven’s application rejected due to Apotex manufacturing issues
Biohaven’s sublingual Riluzole treatment for ALS receives a CRL from the US FDA due to the API being supplied by Apotex.
Gotham, Mercachem create molecule library for RNA-modifying drug discovery
A collaboration between Mercachem and Gotham leads to the generation of a molecule library, expected to enable new discovery opportunities in the epitranscriptomic targets space.
Lovelace, Exemplar to work on Sickle Cell Disease model under NIH contract
Lovelace’s support and the inclusion in a $20m NIH contract enable Exemplar to continue the development of a porcine animal model for Sickle Cell Disease research.
Quotient to ‘stretch’ core CDMO business with new PE owners
Quotient Sciences has found new owners in the UK-based PE firm, Permira, as the CDMO eyes new opportunities to expand its business into adjacent service sectors and new geographies, says CEO.